Question-and-Answer SessionSo perhaps we could start by having you give our audience a brief overview of Entrada Therapeutics and in particular, the Endosomal Escape Vehicles technology platform.Dipal DoshiCEO & Director Yes, happy to do that. So Entrada is a clinical stage biotech company that is aiming to transform patients' lives. We have a proprietary application or technology called Endosomal Escape Vehicles that we also call EEVs. We'll use that interchangeably, which we really believe enhances the va ...

Charles Rotblut, CFA is the editor of the AAII Journal, the flagship publication of The American Association of Individual Investors (AAII). Charles provides both insight about individual investor sentiment and market analysis. He is also the author of "Better Good than Lucky: How Savvy Investors Create Fortune with the Risk-Reward Ratio" (W&A Publishing/Trader's Press).Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate ...

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!In March, I concluded that premium safety manufacturer MSA Safety Incorporated (NYSE: MSA ) was looking to get more safe itself. A premium previously attached to the business had largely come out ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

The stock market is showing signs of strain near all-time highs, as Fed Chair Powell's comments that stocks look expensive are driving a loss of faith in the tech trade that has dominated the market this year. In my view, this is aWith combined experience of covering technology companies on Wall Street and working in Silicon Valley, and serving as an outside adviser to several seed-round startups, Gary Alexander has exposure to many of the themes shaping the industry today. He has been a regular contributor ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

After five years of post-COVID volatility, pet-owning households are expected to increase by 1% each year through 2027, leaving pure play Chewy (NYSE:CHWY) positioned to capture a large chunk of the pet wallet. Betting on the “underdog” in the pet industry, MoffettNathanson raised ...

The Russell 2000 made headlines earlier this month for finally eclipsing its November 2021 all-time high. U.S. small-cap stocks have performed well leading up to and immediately following the Fed's resumption of its rate-cutting cycle . Interestingly, the higher-quality S&P SmallCap 600Freelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firm ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but those who sign up for the yearly plan will be able to take advantage of a 33.50% dis ...